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Raf-1 Kinase Inhibitor Protein Regulates Cell 
Migration and Proliferation of Mouse Embryonic 
Fibroblasts  
 
Donghui Song, B.S. 
University of Connecticut, 2012 
Raf-1 kinase inhibitor protein (RKIP) is a multifunctional protein that plays a 
regulatory role in a variety of biological activities, including cellular signaling 
pathways, cell proliferation, cell migration, cell cycle, apoptosis and cancer 
metastasis. In our previous study, we have identified that RKIP has a positive 
effect on the cell migration in Madin-Darby canine kidney (MDCK) cell line. 
Moreover, we also discovered that a small stretch of amino acids (146-
RGKFKVASRFKK-157) as the nuclear localization signal (NLS) targets RKIP 
for translocation to the nucleus.  In this study, we showed strong evidence that 
RKIP expression has no effect on cell migration in both wild type mouse 
embryonic fibroblasts (MEF), and MEF cells lacking the RKIP gene (MEF RKIP 
-/-
) with RKIP reintroduced. Furthermore, we found that RKIP expression inhibits 
the cell proliferation of the MEF cell line. Furthermore, we found that the nuclear 
localization of RKIP has a regulatory role in cell migration, cell proliferation and 
cell cycle distributions. Interestingly, we have also determined the effects that 
RKIP has on cell migration, cell proliferation and cell cycle distribution are 
independent of MAPK/ERK activation suggesting the involvement of a different 
pathway. 
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CHAPTER I  
INTRODUCTION TO RAF-1 KINASE INHIBITOR PROTEIN AND ITS 
BIOLOGICAL FUNCTIONS 
1.1 An overview of  Raf-1 kinase inhibitor protein 
Raf-1 kinase inhibitor protein (RKIP), a 21 kDa protein with 187 amino acids, has been 
discovered as a member of the phosphatidylethanolamine binding protein (PEBP) family 
[1, 2]. Initially, the name of this protein was phosphatidylethanolamine binding protein 1 
(PEBP1) resulting from its ability to bind weakly with phosphatidylethanolamine [3]. 
With the further study on it, this protein was renamed as Raf-1 kinase inhibitor protein 
(RKIP), because it was found that RKIP can bind to Raf kinase and inhibit the interaction 
between Raf-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase 
1 (MAPK/ERK) [4].  
RKIP is commonly seen in the brain, testis, liver and kidney of mammalian animals [5, 6]. 
As well as the other PEBP family proteins, it has been determined from the 3D X-ray 
crystal structure of RKIP that there are two main domains, ligand binding pocket and 
globular structure [7, 8] (Figure 1). It has been reported that the ligand binding pocket 
provides the binding site not only for phosphatidylethanolamine, but also for the newly 
discovered small molecule inhibitor locostatin [9]. However, the mechanism of binding 
between RKIP and its ligands, as well as the specific amino acid binding sites has not as 
of yet been identified. Furthermore, the globular structure domain also plays a key role in 
a multitude of biological functions, due to its globular surface being able to provide 
2 
 
enough surface area for association with various cellular function modulator proteins. For 
example, previous studies have shown that RKIP is able to interact with several proteins 
that function as cellular signaling pathway regulators, such as Raf-1, B-Raf, 
MAPK/extracellular signal regulated kinase kinase (MEK), G protein coupled receptor 
kinase 2 (GRK2), and nuclear factor κB (NF-κB)-inducing kinase (NIK), transforming 
growth factor (TGF)-β activated kinase 1 (TAK1), inhibitor of κB kinase α (IKKα) and β 
(IKKβ) [4, 10-15]. Although the binding sites of RKIP and most of the proteins described 
above have not been revealed, a critical residue (Ser153) on RKIP was identified to have 
the relationship with the interaction between RKIP and Raf-1 [10]. The evidence has 
shown that RKIP is phosphorylated at Ser153. Further studies have shown that the 
phosphorylation at Ser153 has a crucial role in the regulation of the interaction between 
RKIP and Raf-1. Protein kinase C (PKC) phosphorylates the Ser153 residue leading to 
the dissociation of the RKIP-Raf-1 complex. It has been assumed that the steric hindrance 
contributes more to the dissociation than electrostatic repulsion [10]. Nevertheless, this is 
not the end of this story of the relationship between the structure of RKIP and its 
biological function. There are still many questions, such as the number and location of 
binding sites corresponding to different binding partners that has yet to be determined, so 
that a better understanding of this regulatory protein may be obtained.  
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Figure 1 3D X-ray crystal structure of Raf-1 kinase inhibitor protein (RKIP). The ligand 
binding pocket domain is shown in red. The globular structure domain is shown in blue. 
The phosphorylation site Ser153 residue is shown in green. The figure is referred from 
Expert Opin. Ther. Targets (2008) 12(10): 1275-1287.  
1.2 Biological functions of Raf-1 Kinase Inhibitor Protein  
1.2.1 Role of RKIP in the regulation of signaling pathway 
1.2.1.1 Regulation of Raf-1 signaling pathway 
Numerous experimental findings have revealed the fact that numerous biological 
activities, including cell proliferation, cell survival and cell differentiation, are mediated 
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by the Raf-1/MEK/ERK pathway in which RKIP plays a critical role in modulating the 
aforementioned cell functions [16-22].   
Presented in this thesis is how the Raf-1/MEK/ERK pathway functions at the molecular 
level (Figure 2). Initially, the stimulus from the environment is sensed at the growth 
factor cytokine. The signal is propagated by various growth factors, such as epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF) and nerve growth factor 
(NGF). Afterwards, the receptor tyrosine kinase (RTK) is activated via phosphorylation 
on its tyrosine residue. RTK acts as an initiator for many signaling cascades including 
Raf-1/MEK/ERK and NF-κB signaling cascades [16, 17]. Then RTK activates Ras [23], 
a small protein which belongs to G protein family, through a number of growth factor 
receptor proteins. The growth factor receptor-bound protein 2 (Grb-2) and its domain, son 
of sevenless (SOS), are also involved in this Ras activation process. SOS on Grb-2 
interacts with Ras through its GTP exchange factor (GEF) domain, where GDP is 
phosphorylated to GTP [23-25]. After Ras is activated, it binds with Raf-1 kinase and 
activates it [26]. Subsequently, activated Raf-1 phosphorylates and activates 
MAPK/extracellular signal regulated kinase kinase (MEK) directly. In the same way, 
MEK then activates extracellular signal-regulated kinase (ERK) by phosphorylation [27]. 
To our knowledge, the Raf-1/MEK/ERK signaling pathway has a crucial function in the 
modulation of the gene expression. In the nucleus of the cell, phosphorylated ERK 
converts Fos proteins to Fos phosphoproteins [28]. When phosphorylated Fos proteins 
bind with the transcription factor activation protein 1 (AP-1), AP-1 is then activated and 
associates with the 12-O-tetradecanoyl phorbol-13-acetate (TPA) response element (TRE) 
[29- 32]. As a result, the stimuli from the environment affect gene expression leading to 
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the modulation of biological activities. For example, when the signal impacts Bcl-2 gene 
expression through Raf-1/MEK/ERK signaling pathway, the cell apoptosis is modulated 
accordingly [33-35]. In other words, Bcl-2 is able to regulate cell. Moreover, besides Bcl-
2, many more genes including cyclin-dependent kinases (CDKs), Bcl-xL and Mcl-1 are 
also involved in the signaling pathway to regulate some certain biological process, such 
as cell proliferation, apoptosis, differentiation and migration [36-38]. Thus, disruption of 
any part of the Raf-1/MEK/ERK signaling pathway will lead to a deleterious effect in the 
behavior of the cell resulting in many human diseases such as cancer. 
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Figure 2 The Raf-1/ MEK/ERK signaling pathway. This signaling pathway plays a key 
role in transferring signal from cell membrane to the nucleus, leading the AP-1 
transcription. The main direction of the signal transduction can be described like this: 
RTKGrb-2RasRaf-1MEKERKAP-1gene expression. The figure is 
referred from Adv Cancer Res (2004) 91: 169-200. 
After the discovery of the Raf-1/MEK/ERK signaling cascade, the regulation process has 
remained complex and difficult to understand until Kam Yeung et al. identified RKIP as 
an inhibitor of this signaling pathway [4]. As we know, Raf-1 associates with MEK and 
activates it by phosphorylation. Experimental results have shown that overexpression of 
RKIP decreases the efficiency of the signaling pathway by disrupting the association 
between Raf-1 and MEK. Subsequently, the phosphorylation of MEK is inhibited, so that 
ERK cannot be phosphorylated and activated by MEK. As such, the signal stops at the 
Raf-1-MEK complex and thus cannot be transferred to MEK. As a consequence, RKIP is 
discovered as having an inhibitory function on Raf-1/MEK/ERK cascade. A model has 
been made to explain the mechanism of the RKIP inhibitory function. RKIP is considered 
as a competitive inhibitor of the association between Raf-1 and MEK (Figure 3). The 
result from binding site mappings among RKIP, Raf-1 and MEK definitely proves this 
conclusion [14]. It is well known that RKIP is able to bind physically with both Raf-1 
and MEK. It leads to the disruption of their association and prevents phosphorylation of 
MEK. Additional data was also found to provide more evidence for this mechanism. In 
vitro, it was identified that mitogens can down-regulate the association of RKIP and Raf-
1. Interestingly, the signaling pathway is recovered through the negative regulation with 
mitogens. Thus, we believe that the molecular mechanism model shown in Figure 3 best 
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elucidates the role that RKIP plays in the inhibition of Raf-1/MEK/ERK signaling 
pathway. 
 
Figure 3 A proposed mechanism of inhibition of the Raf-1/MEK/ERK signaling pathway 
by RKIP. The signal propagates only when the Raf-1 binds to MEK and activates it by 
phosphorylation. Overexpressed RKIP disrupts the association between Raf-1 and MEK. 
Then no signal comes out with the suppression function by RKIP. However, he signal is 
dramatically enhanced when the mitogens is used to dissociate the Raf-1-RKIP complex. 
Therefore, both of the experimental result described above shows that RKIP plays a role 
in reducing the signal in the pathway. The figure is referred from Mol. Cell. Bio. 2008 
20(9): 3079-3085. 
In addition to the inhibitory function by RKIP, recent studies show that Raf-1/MEK/ERK 
signaling pathway can be positively regulated by protein kinase C (PKC) [10, 39] (Figure 
4). The PKC is a form of serine/threonine kinase that mediate the Raf-1 cascade by 
phosphorylating RKIP. It is already known that G protein coupled receptors (GPCRs) 
induce the PKC phosphorylation of the Serine 153 residue on RKIP when the cell is 
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stimulated. The phosphorylation on Ser153 leads to the dissociation of the Raf-1-RKIP 
complex possibly due to steric hindrance. As a consequence, the PKC prevents the 
suppression of Raf-1 cascade by RKIP. We also know that the PKC functions not only as 
an activator for Raf-1 [40-42], but also as an activator for MEK for the reason that they 
can phosphorylate MEK as well [43]. Thus, the PKC can be considered as an up-
regulator for the Raf-1/MEK/ERK signaling pathway. However, the mechanism that the 
down-regulation by RKIP and up-regulation by PKC work coordinately to mediate the 
physiological process in the cell is still unclear. In that, we still do not know when the 
positive mediation is dominant, or under what conditions the negative modulation 
displays more apparently. 
 
Figure 4 Raf-1 signaling pathway is regulated by both RKIP and PKC. By binding to 
Raf-1 and MEK, RKIP prevents the Raf-1 binding with and phosphorylating MEK. Here 
RKIP is considered as a downstream suppressor. By phosphorylating the Serine 153 
residue on RKIP, PKC induces the dissociation between Raf-1 and MEK, which in turn 
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acts as an upstream activator. The figure is referred from Molecular Cell Biology (2005) 
6: 827-837. 
Although this signaling cascade was mapped years ago and a great progress has been 
made in the study on it, there are still many unsolved problems on the modulation of Raf-
1/MEK/ERK signaling pathway including what other specific proteins besides RKIP 
participate in regulation, the mechanism of modulation, what are the binding sites 
between the regulator proteins and their binding partners involved in the pathway and the 
timing of phosphorylation and de-phosphorylation of the kinases in the cascades. 
1.2.1.2 Regulation of NF-κB signaling pathway 
Similar to the Raf-1 signaling pathway, the NF-κB pathway is also characterized as a key 
modulator for many physiological functions, including cell growth, cell apoptosis, cell 
adhesion and immunity [44-50]. Errors in the NF-κB pathway are found to be responsible 
for cancer, inflammation, neurological disease, and improper immune development [51-
55]. RKIP participates in not only the regulation of Raf-1 cascade we introduced above, 
but also that of NF-κB signaling pathway. Moreover, RKIP is reported to have an 
inhibitory function on NF-κB pathway [56]. 
The transcriptional activator nuclear factor kappa B (NF-κB) is a form of REL family 
dimeric protein [57] which is essential for regulating gene expression which is 
responsible for cell proliferation, survival, adhesion and immunity. Recent studies have 
revealed that gene expression related to NF-κB is activated by several kinds of stimuli, 
such as stress and inflammation [58]. Based on the fact that proinflammatory cytokines 
interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) are activators for the 
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NF-κB signaling pathway [59, 60], they stimulate the transforming growth factor β-
activated kinase 1 (TAK-1) and NF-κB-inducing kinase (NIK) upon binding with tumor 
necrosis factor receptor 1 (TNF-R1) [24]. Afterwards, as the signal continues to be 
propagated when the TAK-1 and NIK activate by phosphorylating the IκB (inhibitor of 
NF-κB) kinase (IKK) which contains two subunits IKKα and IKKβ [61-70]. 
Subsequently, IKK activates and phosphorylates IκB, afterwards phosphorylated IκB is 
degraded by 26S proteasome. As a consequence, the phosphorylation and degradation of 
IκB causes the NF-κB to depart from the IκB-NF-κB complex. Finally, upon dissociation 
with IκB, NF-κB translocate to the nucleus and regulate the gene expression that 
responds to the NF-κB signaling pathway [71] (Figure 5). 
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Figure 5 The NF-κB signaling pathway. The NF-κB cascade is initiated by TNF-α which 
acts as a signal activator. The signal is propagated as follows: TAK-
1/NIKIKKα/βIκB/NF-κB NF-κBgene expression in nucleus. The figure is 
referred from Adv Cancer Res (2004) 91: 169-200. 
Kam Yeung et al. demonstrated that RKIP can modulate the NF-κB signaling pathway, 
as well as the Raf-1 signaling pathway [56]. It is significant that RKIP is able to regulate 
two different pathways which are independent of each other. In their study, RKIP is 
discovered as an inhibitor of NF-κB release so that it down-regulates the NF-κB signaling 
pathway. Although the detailed mechanism of the inhibitory function by RKIP still 
remains unknown, what we can recognize is that RKIP can prevent the phosphorylation 
of IKKα and IKKβ by associating with TAK-1 and NIK. It is very similar with 
mechanism that RKIP negatively regulates the Raf-1 cascade by interacting with Raf-1 
and MEK, which blocks the phosphorylation and activation of MEK. Furthermore, 
another model was built to show that RKIP can also interact with IKKα and IKKβ [72]. 
This interaction leads to the blocking of the phosphorylation on IκB, so that IκB cannot 
be degraded and NF-κB cannot be released to regulate the gene expression. Taken 
together, RKIP is found to interact with four important kinases involved in the NF-κB 
signaling pathway, including TAK-1, NIK, IKKα and IKKβ, which cause the 
deactivation of NF-κB. Therefore, RKIP here acts as a down-regulator for the NF-κB 
cascade. 
1.2.1.3 Regulation of GPCR signaling pathway 
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Previous studies have revealed that GPCR is yet another important signaling pathway 
which serves as a modulator for a variety of biological processes, including inflammation, 
hormone and blood pressure regulation [73]. As it is shown in the Raf-1 pathway, PKC 
phosphorylates RKIP on it Serine 153 site and leads to the dissociation of Raf-1-RKIP 
complex. Then the phosphorylated RKIP departs from Raf-1 and bind to G protein 
coupled receptor kinase 2 (GRK-2), which is a suppressor for the stimulation of G protein 
coupled receptors (GPCRs) through their phosphorylating [10, 11, 74], leading to the loss 
of inhibitory activity of GRK-2. As a result, the GPCR signaling pathway is promoted 
because the deactivation of GRK-2 by the PKC-mediated phosphorylation of RKIP 
(Figure 6). Therefore, RKIP we report here works as a positive modulator for this 
pathway.  
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Figure 6 An overview scheme for the role of RKIP in Raf-1, G protein coupled receptor 
(GPCR) and NF-κB signaling pathways. The figure is referred from Expert Opin. Ther. 
Targets (2008) 12(10): 1275-1287. 
1.2.2 Role of RKIP in cell cycle 
Cell cycle, which is also called cell-division cycle, is a series of events involved in the 
cell division process. In the eukaryotes cells, a cell cycle starts at a resting phase (G0 
phase) during which the cell has left the previous cycle and is ready for the next cycle. 
Then the next step of a cell cycle is interphase including G1, S and G2 phase, during 
which the cell keeps growing, replicates its DNA and gets everything ready for its final 
step – mitosis phase. In the mitosis phase (M phase), the cell stops growing and it is 
eventually orderly divided to two daughter cells [75, 76].  
Many recent studies on the relationship between RKIP and the cell cycle have 
demonstrated that RKIP does play a key role in cell cycle regulation. Like the other 
physiological processes, cell cycle is also modulated by multiple signaling pathways. 
Raf-1/MEK/ERK as discussed above is reported to be one of the signaling cascades that 
function as a modulator of cell cycle [77]. The cell cycle is ended at mitosis phase during 
which a spindle checkpoint is formed in the middle of the mitosis [78, 79]. The spindle 
checkpoint is considered to be a monitor for making sure the kinetochore is attached to 
the correct position of the chromosomes, so that all replicated chromosomes can be 
divided equally and orderly to the two daughter cells. As a consequence, it is obvious that 
genomic stability is determined by the formation of this spindle checkpoint. Recent 
reports have revealed that RKIP is able to modulate the formation of the checkpoint by 
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inhibiting Aurora B kinase [80] (Figure 7). As it was mentioned previously, RKIP 
inhibits the Raf-1 signaling pathway by interrupting the interaction between Raf-1 and 
MEK. So it can be clearly seen that the depletion of RKIP leads to the hyper-activation of 
Raf-1 cascade, which is found to be a reason for down-regulating the Aurora B kinase [81, 
82]. The inhibition of Aurora B kinase by RKIP results in abnormal separation of the 
chromosomes which may bring about cell apoptosis or even ontogenesis [83].  
Furthermore, Al-Mulla et al. recently reported that depletion of RKIP in HEK 293 cells 
enhances the rate of the cell proliferation [84]. The proposed mechanism is related to the 
glycogen synthase kinase-3β (GSK3β) pathway. It has been shown that the GSK3β 
inhibits the activation of cyclin D1, which plays an important role in cell cycle. RKIP is 
known to act as a deactivator of GSK3β [85]. Thus, RKIP here works for stabilizing the 
cyclin D1. The acceleration of cell proliferation can be well explained by this significant 
finding. As with cyclin D1, there may be other gene regulatory proteins involved in cell 
cycle that are modulated by RKIP [86-88]. In the case of RKIP silencing, it is apparent 
that the expression and functions of these gene regulatory proteins are impacted. A 
proposed explanation for the higher rate of cell proliferation is that the depletion of RKIP 
induces some genes involved in interphase and mitosis phase abnormally expressed 
which leads to the reduction of time in G1/S and G2/M phase transition. 
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Figure 7 Regulation of spindle checkpoint by RKIP. The formation of the checkpoint in 
the cell cycle process is directly modulated by Aurora B kinase, which is effected by the 
Raf-1/MEK/ERK signaling pathway. In the case when RKIP is depleted, the hyper-
activation of the Raf-1 cascade inhibits Aurora B kinase, thereby leads to the abnormal 
cell cycle. The figure is referred from Expert Opin. Ther. Targets (2008) 12(10): 1275-
1287. 
1.2.3 Role of RKIP in apoptosis 
Apoptosis is known as a biological process of programmed cell death (PCD) which 
usually takes place in multicellular organisms [89-91]. Compared with necrosis, 
apoptosis is a normal biological activity which is considered as an advantageous 
phenomenon in the life cycle [92]. For example, there are 50 – 70 billion cells die each 
day due to apoptosis in a human adult [93]. As we know, apoptosis plays a critical role in 
human health. Deregulation of cell apoptosis pathway may cause drug resistance. The 
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drug resistant cells may become cancer cells when they lose the apoptotic function [94-
96]. Nowadays, chemotherapeutic drugs or irradiation induced apoptosis has been widely 
used as a therapeutic treatment of cancer. 
As it was described in the role of RKIP in signaling pathway, there are two major 
pathways that are able to regulate cell apoptosis by mediating the gene expression. They 
are Raf-1 and NF-κB cascades. Since it is already known that RKIP inhibits both of these 
two signaling pathways, it is very likely RKIP also has an effect on the regulation of cell 
apoptosis (Figure 8). Recently, many studies have provided enough evidence for the role 
of RKIP in cell apoptosis. In non-Hodgkin’s lymphoma B cells, RKIP expression is 
induced by the chemotherapy drug which is called Rituximab [97]. Consequently, 
induced expression of RKIP then inhibits the Raf-1 pathway and leads the cell death. 
Moreover, in RKIP overexpressed prostate and melanoma cells, the cell apoptosis is 
found to be regulated through NF-κB pathway [98]. Here, the apoptosis of the cells is 
stimulated by death receptor ligands, such as tumor necrosis factor α (TNF-α), TNF-
related apoptosis-inducing ligand (TRAIL), and Fas ligand (FasL) [99]. Therefore, these 
results clearly illustrate that RKIP functions as a modulator for cell apoptosis by 
inhibiting either Raf-1 or NF-κB pathway.  
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Figure 8 Model of RKIP up-regulating chemotherapy drug-induced cell apoptosis. 
Chemotherapy drug-induced expression of RKIP promotes the cell apoptosis by 
inhibiting Raf-1, NF-κB pathways or both simultaneously. The figure is referred from 
Expert Opin. Ther. Targets (2008) 12(10): 1275-1287. 
1.2.4 Role of RKIP in cancer metastasis 
Cancer metastasis is defined as a cancer cells leaving the original tumor and colonizing 
other tissues, forming secondary tumors and aggravating the disease [100, 101]. Thus, 
research in cancer metastasis inhibition has becoming a pressing topic. Here we report the 
function of RKIP in the regulation of tumor metastasis. RKIP was initially found to have 
lower expression in C4-2B cells (a form of metastatic prostate cells) compared with its 
expression in LNCaP (a form of nonmetastatic prostate carcinoma cells, the parental cells 
of C4-2B cells) [102]. Moreover, reduced or nonexpression of RKIP was subsequently 
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discovered in other cancer or tumor cell lines, including breast cancer [103], colorectal 
cancer [104-106], anaplastic thyroid cancer [107], hepatocellular carcinoma [108, 109], 
insulinomas [110] and melanoma [12, 111]. In addition, there is no effect on the growth 
of the primary tumor cells when the RKIP is overexpressed. The overexpression of RKIP 
is only found to inhibit the tumor invasion. Therefore, these findings show that RKIP can 
be regarded as a potential suppressor of cancer metastasis.  
However, there is little known about the mechanism of the regulation of cancer 
metastasis by RKIP. One proposed mechanism is that RKIP modulates the metastasis by 
controlling the apoptotic pathway. The abrogation of the cell apoptosis process is one 
aspect that leads to cancer. RKIP is discovered as an inhibitor of Raf-1 and NF-κB 
signaling cascades which are responsible for cell apoptosis. In the tumor cells, the lack of 
RKIP may cause the disruption of these two key signaling pathways. As a consequence, 
the apoptotic signal is disrupted, so that the tumor cells with low RKIP levels show 
resistance to apoptosis leading to their metastasis [112]. However, some recent reports 
demonstrate the opposite opinion to the mechanism above. Their results have shown the 
fact that knockdown of RKIP in Merkel cell does not affect the level of phosphorylation 
of ERK [113]. Thus, it seems that the mechanism of how RKIP regulates metastasis is 
still poorly understood. Much work is required to be done to get a definitive answer to 
this problem. 
1.2.5 Role of RKIP in cell migration 
Cell migration is a multi-step process that involves dynamic assembly and disassembly of 
cytoskeleton, attachment and detachment to extracellular proteins, and translocation of 
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the cell, which plays a key role in many biological processes including embryonic 
development, immune function, and wound healing [114]. Moreover, errors in cell 
migration cause some diseased processes such as tumor formation, cancer cell invasion 
and metastasis [115].  
By now, the relationship between RKIP and cell migration is not clearly understood, due 
to the conclusions made by different investigators are controversial. In our previous study, 
Zhu et al. demonstrated that knockdown RKIP decreases the rate of cell migration of 
Madin-Darby canine kidney (MDCK) epithelial cells. Moreover, they discovered a small 
molecule inhibitor of RKIP, locostatin, inhibits the activity of RKIP by disrupting the 
association between RKIP and Raf-1 [116]. Based on the function of locostatin, we 
previously reported that the cell migration rate of RKIP overexpressed MDCK cell is 
dramatically higher than that of normal MDCK cells. In addition to it, we also found cell 
migration rate of RKIP overexpressed MDCK cell treated with locostatin is slower than 
that of the control. Taken together, our previous study reveals that RKIP plays a positive 
role in cell migration. However, opposite conclusion of the function of RKIP on cell 
migration was made by other groups. They demonstrated that the overexpression of RKIP 
leads to the decrease of the rate of cell migration in other cells, such as hepatoma and 
malenoma cell lines [84, 109, 117]. These contradictory findings show that the effect 
RKIP on cell migration is cell line dependent. The detailed mechanism for the role of 
RKIP in cell migration requires further study. 
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CHAPTER II  
RAF-1 KINASE INHIBITOR PROTEIN NUCLEAR LOCALIZATION HAS A 
REGULATORY EFFECT ON CELL MIGRATION AND PROLIFERATION 
INDEPENDENT OF THE MAPK/ERK PATHWAY 
2.1 Introduction 
Raf-1 kinase inhibitor protein (RKIP) is a 21 kDa protein that was initially discovered as 
a member of phosphatidylethanolamine-binding protein (PEBP) family and named 
PEBP1, as it weakly binds to phophatidylethanolamine [118, 119]. PEBP1 was renamed 
as RKIP since it was found to inhibit Raf-1 kinase. From numerous experimental results, 
RKIP has been discovered as an essential protein in many signaling pathways. In the Raf-
1/MEK/ERK signaling pathway, RKIP binds to Raf-1 kinase [120, 121] and disrupts the 
interaction between Raf-1 and mitogen-activated protein kinase/extracellular signal-
regulated kinase 1 (MAPK/ERK), thus preventing phosphorylation and activation of 
MEK1 and results in the negative regulation of the Raf-1 signaling cascades [120, 121]. 
As we know, phosphorylation on the serine 153 residue of RKIP by Protein kinase C 
(PKC) leads to dissociation between RKIP and Raf-1. This results in a new association 
between RKIP and G protein-coupled receptor kinase 2 (GRK2) [122, 123]. In GPCR 
signaling pathway, GRK2 phosphorylates G protein-coupled receptors (GPCRs) leading 
to an internalization of the receptors and subsequent inhibition of their signaling activity 
[123].  The association between RKIP and GRK2 results in the inactivation of GRK2 
which leads to a positive regulation of GPCR signal receptor activation [123].  
Furthermore, RKIP expression has also been found to antagonize the activation of the 
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NF-B pathway [124, 125]. In the NF-B signaling pathway, RKIP was found to interact 
with the following kinases involved in the NF-B cascade: transforming growth factor -
activated kinase 1 (TAK1) [124], nuclear factor B (NF-B)-inducing kinase (NIK) 
[124], inhibitor of B kinase  (IKK) and  (IKK) [124]. To our knowledge, the 
interaction between RKIP and the four kinases listed above is regarded as a supposed 
mechanism of the down-regulation of   NF-B signaling pathway by RKIP.  Recently, it 
was discovered that RKIP enhances GSK3 signaling by stabilizing GSK3 [126].  
Interestingly, the aforementioned RKIP modulated signaling pathways have all been 
shown to play a role in cell cycle progression [127-132].  However, the physiological role 
of RKIP is not limited to cell proliferation.  RKIP has also been associated with apoptosis 
[133-136], cell adhesion [137], cell migration [128, 136-145], and as a tumor suppressor 
in a wide variety of cancer cell types [127, 128, 133, 134, 141, 146-159].  These studies 
suggest that the biological effects of RKIP are quite complex and cannot be elucidated by 
one pathway.  
In order to formulate a conceivable mechanism by which RKIP regulates biological 
activities such as cell migration and proliferation, we have studied exhaustively on the 
relationship between localization of RKIP to the nucleus and the biological activities 
modulated by RKIP. To our knowledge, it has been reported that RKIP is able to 
translocate in the nucleus [129, 130]. However, the mechanism of RKIP translocation 
still remains unclear. So far, two mechanisms have been discovered as the pathways by 
which the small size proteins are transported into the nucleus.  Proteins with a molecular 
mass is lower than 45 kDa are believed to translocate to the nucleus via passive diffusion. 
Thus, the translocation mechanism of RKIP was believed to be by passive diffusion due 
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to its limited size (For a review, see ref. [161]). For the proteins greater than 45kDa, the 
transportation of the proteins from the cytoplasm to the nucleus depends on the importin 
superfamily which is functions as transport proteins. In this translocation mechanism, 
nuclear localization signal (NLS), which is a short stretch of amino acids on the protein 
being transported. NLS plays a key role in the recognition between the target proteins and 
importin. Proteins with NCL are initially recognized by a heterodimer importin α/β, then 
translocated into the nucleus. In collaboration with Christian Argueta, we have previously 
reported that a small stretch of amino acids (146-RGKFKVASRFKK-157) is the NLS 
targets RKIP to the nucleus. Our experimental results demonstrated that the nuclear 
localization signal (NLS) on RKIP binds to the nuclear transport protein importin  and 
ultimately leads to nuclear translocation.  
Based on the discovery of the nuclear localization signal on RKIP, we have done 
considerable work to determine if there is any connection between the nuclear 
localization of RKIP and cell migration and proliferation. Initially, we chose wild type 
RKIP expressing mouse embryonic fibroblasts (MEF RKIP
+/+
) cells to conduct the 
experiment. Interestingly, the mouse embryonic fibroblasts cells with green fluorescence 
protein (GFP) labeled RKIP expressed (MEF RKIP
+/+ 
+ GFP-RKIP) have a slightly 
higher rate of cell migration than wild type RKIP expressing mouse embryonic 
fibroblasts (MEF RKIP
+/+
) cells. In addition to this result, we discovered that MEF 
RKIP
+/+
 cells with NLS deficient mutants of RKIP expressed have a visibly slower rate of 
cell migration than the wild type MEF RKIP
+/+
 cells. Therefore, we can draw a 
conclusion that the nuclear localization of RKIP does have an obviously regulatory effect 
on the cell migration of MEF cell line. Furthermore, we also worked on exploring if NLS 
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has the same regulatory effect on cell proliferation.  To our surprise, the cell proliferation 
result fails to prove this assumption. We found that MEF RKIP
+/+ 
+ GFP-RKIP cells have 
a slower rate of cell proliferation than MEF RKIP
+/+
 cells. However, some of MEF 
RKIP
+/+
 cells expressing NLS deficient RKIP mutants have a higher rate of cell 
proliferation than MEF RKIP
+/+
 cells, whereas some of them have the opposite effect. 
Thus, we failed to see the nuclear localization of RKIP in MEF cell line plays a role in 
regulating the cell proliferation process.  
Previous studies have been conducted on cells that are over-expressing RKIP or have 
knocked down the expression of RKIP. Recent studies have shown that RKIP depletion 
regulates the transcription of proteins involved in both cell migration and proliferation 
[128]. A few studies have gone so far as to completely remove RKIP from the mouse 
embryonic fibroblasts (MEF) [130, 139].  These studies have shed valuable light on the 
function of RKIP, and prompted us to see if we could determine whether RKIP had the 
same effect when it is reintroduced in to cells lacking the gene for RKIP. We believe the 
work on the cells lacking gene for RKIP is a complementary step to explain the cell 
migration and proliferation result we found before. With this new method, we can clearly 
see if RKIP is the main factor that plays an essential role in the regulation of cell motility 
and growth. Moreover, downregulation of RKIP has been previously shown to promote 
the activation of Raf-1 cascade in several cell lines. However, the modulation on Raf-
1/MEK/ERK pathway is ambiguous and still poorly understood. A few evidences so far 
cannot prove that RKIP always has the regulatory function in inducing the activation of 
Raf-1 signaling pathway. It is already known that different cell systems present different 
results. Therefore, we can also use the mouse embryonic fibroblasts completely lacking 
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RKIP (MEF RKIP
-/-
) cell line to verify if RKIP has the same function on the activation 
process of Raf-1/MEK/ERK signaling pathway. 
Here we reported that RKIP promoted the rate of migration when we reintroduced RKIP 
to MEF cells completely lacking RKIP. RKIP also inhibited proliferation in MEF cell 
line. The effects that RKIP has on cell migration and proliferation could be linked to its 
nuclear localization. We identified that GFP-RKIP expressing RKIP
-/- 
cells had a 
significantly lower number of cells in G2/M phase when compared to RKIP
-/-
 cells. We 
also found that RKIP had no effect on Raf activation in serum-stimulated cells.   
2.2 Materials and Methods 
Cell culture 
Mouse embryonic fibroblasts (MEF) expressing RKIP (wild type RKIP
+/+
) and MEF 
deficient in RKIP (homozygous RKIP
-/-
) were provided by Prof. Kam Yeung and 
cultured in Dulbecco’s modified Eagles medium (DMEM) containing 10% fetal bovine 
serum (FBS) in a humidified incubator at 37 
o
C with 5% CO2. Early passages of cells 
cultured from frozen stock cultures were used in all experiments. Main cultures were 
grown in 75cm
2
 tissue culture flasks with medium changed every two days. When the 
cultures reached 90% confluence, the cells were gently washed twice with phosphate 
buffered saline (PBS), and treated with a solution of trypsin/ ethylenediaminetetraacetic 
acid (EDTA) in PBS to detach cells from the flasks. After cells were detached, an equal 
volume of fresh medium was added to inhibit the trypsin activity. The cells were 
resuspended in media and cell density was determined with a hemacytometer. Cells were 
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replanted in fresh medium in new tissue culture flasks for continued culture and multi-
well tissue culture plate for experiments. 
Construction of stably transfected cell lines 
Human RKIP was cloned in to the pEF6-myc-his B vector containing green fluorescent 
protein (GFP; a kind gift of Prof. David Knecht) in cloned into its Eco RI and Eco RV 
sites. The point mutants were constructed with the following primers: 
R146N: 5'-AACCGATCTGGAGACCACAATGGCAAATTCAAGGTGGC-3' and 5'-
GCCACCTTGAATTTGCCATTGTGGTCTCCAGATCGGTT-3' 
K148N: 5'-AGACCACCGTGGCAATTTCAAGGTGGCGTC-3' and 5'-
GACGCCACCTTGAAATTGCCACGGTGGTCT-3' 
K150N: 5'-GACCACCGTGGCAAATTCAATGTGGCGTCCTT-3' and 5'-
AAGGACGCCACATTGAATTTGCCACGGTGGTC-3' 
R146N, K148N, K150N: 5'-
CCGATCTGGAGACCACAATGGCAATTTCAATGTGGCGTCCTTCCGTA-3' and 5'-
GGCTAGACCTCTGGTGTTACCGTTAAAGTTACACCGCAGGAAGGCAT-3' 
R155N: 5'-AATTCAAGGTGGCGTCCTTCAATAAAAAGTATGAGCTCAGGG-3' and 
5'-CCCTGAGCTCATACTTTTTATTGAAGGACGCCACCTTGAATT-3' 
K156N: 5'-GTGGCGTCCTTCCGTAATAAGTATGAGCTCAGGG-3' and 5'-
CCCTGAGCTCATACTTATTACGGAAGGACGCCAC-3' 
K157N: 5'-GTGGCGTCCTTCCGTAAAAATTATGAGCTCAGGGC-3' and 5'-
GCCCTGAGCTCATAATTTTTACGGAAGGACGCCAC-3' 
R155N, K156N, K157N: 5'-
AAATTCAAGGTGGCGTCCTTCAATAATAATTATGAGCTCAGGGCCCCGGTG-3' 
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and 5'-
CACCGGGGCCCTGAGCTCATAATTATTATTGAAGGACGCCACCTTGAATTT-3' 
R155N, K148N, K150N, R155N, K156N, K157N: 
5'AATTTCAATGTGGCGTCCTTCAATAATAATTATGAGCTCAGGGCCCCGGGG-
3' and 5'-
CCCCGGGGCCCTGAGCTCATAATTATTATTGAAGGACGCCACATTGAAATT-3' 
All GST-tagged rat RKIP (a kind gift of Prof. Kam Yeung) deletion mutant constructs 
were cloned in the pEF6-GFP-Myc-His B vector in between the Eco RV and Not I sites 
using the following primers: 
GST fusion: 5’-ATAGCGCGCGATATCATGTCCCCTATACTAGG-3’ and 5’-
ATAGCGGCCGCTCACGATGAATAAGCTT-3’ 
Once sequenced, the vectors were transfected using Lipofectamine 2000. 
The GFP-NLS fusion construct was created by PCR amplification of the NLS with the 
following primers: 
NLS fusion:5’-GCGCGCATAGAATTCTCGTGGCAAATTCAAG-3’ and 5’-
GCGCGCATAGATATCCTTTTTACGGAAGGACG-3’ 
The amplification product was then digested with Eco RI and Eco RV and ligated into the 
pEF6-GFP-Myc-His B vector.   
Once sequenced, the GFP tagged Human RKIP and RKIP mutant proteins vectors 
described above were transfected in to MEF
+/+
 and MEF
 -/-
 cells with Lipofectamine 2000 
(Invitrogen) and selections was performed with 10 µg/mL Blasticidin S (InvivoGen) for 
three weeks.  After selection the cells were cultured in DMEM containing 10% FBS with 
10 µg/mL Blasticidin S. 
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Wound closure assay 
All of the MEF created were plated on to 24-well tissue culture plates at a density of 
1x10
5
 cells/mL and allowed to reach confluence.  Once confluent the cells were treated 
with 10 µg/mL Mitomycin C and wounded manually with a small 0.5-10 µL pipette tip.  
After 3 hours the media was replaced with fresh DMEM and the experiment continued 
until the wounds were completely closed.  Digital images were acquired as soon as the 
wounds were made and at 3, 6, 9, 12, and 24 hours post wounding.  The open wound 
areas were obtained using NIH Image J software and were subsequently plotted against 
time using GraphPad Prism software [136].   
Cell Proliferation 
Cell proliferation was measured using the CCK-8 kit as described by Dojindo. MEF cells 
(124µL of a 4x10
4
 cells/mL in DMEM growth medium) were plated in to two 96-well 
tissue culture plates and incubated at 37 
o
C for 24 hours.  After 24 hours one plate was 
treated with WST-8 (CCK-8; Dojindo) in order to determine cell density at the start of 
the experiment.  The parallel plate was treated with WST-8 48 hours later and compared 
to the numbers generated from the first plate.  A ratio of 48hr/24hr was obtained for each 
MEF cell line generated and plotted using GraphPad Prism. 
Cell cycle analysis 
MEF were plated at a density of 2x10
6
 cells/mL and allowed to adhere overnight.  24 
hours later, the cells were washed three times with 1x Phosphate Buffered Solution (PBS) 
and trypsinized for 30 minutes. The cells were pelleted by centrifugation at 1000 rpm for 
3 minutes and washed three times with PBS. The cells were then resuspended in mL PBS 
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and fixed by adding ice-cold ethanol drop-wise with vortexing to prevent aggregation. 
The cell suspension was then incubated overnight at 4
o
C. Following the fixation process, 
the cells were pelleted and washed 3 times and resuspended in PBS containing 0.1% 
Triton X-100, 250 µg/mL RNAse and 50 µg/mL propidium iodide for 1 hour. Cell cycle 
analysis was performed by flow cytometry (BD Calibur, BD Biosciences) and analyzed 
using Cell Quest software. 
Raf activation assay 
MEFs were plated at 1x10
5
 cells/mL in 6-well tissue culture plates and allowed to reach 
confluence. Once confluent, the cells were serum starved for 48 and activation was 
achieved by reintroducing FBS into their medium. After 30 mintues the cells were lysed 
in 100µL 2x SDS sample buffer and scraped into a centrifuge tube. The samples were 
boiled for 10 minutes and subsequently centrifuged at 15000 rpm for 10 minutes. After 
centrifugation, the samples were subjected to SDS-PAGE and transfected to 
polyvinyldifluoride membrane. ERK activation was determined using the rabbit anti 
phospho p-44/42 MAPK antibody (Cell Signaling Technology). The primary antibody 
was probed with a goat anti-rabbit HRP antibody (Santa Cruz Biotechnology) with 
visualization by enhanced chemiluminescence. 
Raf pull-down assay 
Raf pull down assays were performed by plating MEFs at 2x10
5
 cells /mL in 100 mm 
dishes. The cells were allowed to adhere overnight and well lysed the following morning 
using ice cold 1xPBS supplemented with protease inhibitors (sigma) and 0.25% Triton X-
100 for 30 minutes. The samples were then centrifuged at 15000 rpm to remove any 
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insoluble debris and the GFP fusion proteins were pulled down by incubating an anti-
GFP (FL) antibody (Santa Cruz Biotechnology) for 3 hours followed by protein G 
magnectic beads for 1 hour.  The beads were pelleted by at 1000 rpm for 3 minutes and 
washed 3 times with PBS. The pellets were resuspended in 100 µL 2x SDS sample buffer 
and subjected to SDS PAGE. The samples were transferred to PVDF and probed with a 
rabbit anti Raf-1 (C-12) antibody (SantaCruz Biotechnology). The Raf-1 antibody was 
probed with a goat anti rabbit HRP antibody and visualized by enhanced 
chemiluminescence. 
2.3 Results 
RKIP has no effect on cell migration 
We have previously shown that RKIP expression de-regulates cell cell adhesion and that 
cells treated with a RKIP inhibitor migrated at a slower rate in Madin-Darby canine 
kidney cells [140]. To determine whether RKIP has any effect, positive or negative, on 
cell migration in MEF cells, we reintroduced RKIP into MEF RKIP
+/+
 and MEF RKIP
-/-
 
cells.  The cells were treated with Mitomycin C (MMC) to eliminate the effect cell 
division and proliferation would have on the rate of wound closure. Following treatment 
the cells were scratch wounded with a sterile micropipette tip.  The rate of migration was 
measured as function of wound area plotted against time until the wound was 100% 
closed (roughly 24 hours).  Comparing the wound closure rate of MEF
+/+ 
and that of 
MEF
+/+
 GFP RKIP, we can see there is no visible differences between rates of migration 
relevant to the amount of RKIP expression (Fig.1A). We can also draw a conclusion that 
GFP introduced in MEF
+/+ 
does not have any effect on cell migration (Appendix Fig.2). 
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Therefore, we believe that RKIP is the only factor that controls the modulation of cell 
migration. We then reintroduce RKIP to MEF RKIP
-/-
 cells to see what role of RKIP can 
play in cell migration. To our surprise, MEF
-/-
 GFP RKIP has a dramatically higher rate 
of migration than MEF
-/- 
(Fig.1B). Although there is no obviously difference in the rates 
of migration between MEF
+/+ 
and MEF
-/-
, we can still find that MEF
+/+ 
migrates very 
slightly faster than MEF
-/-
. Therefore, these strong evidences reveal that RKIP has no 
effect on cell migration of MEF cell line. 
 
Fig. 1A Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP cells in the 
presence of mitomycin C. we cannot see there is any visible difference between rates of 
migration relevant to the amount of RKIP expression. 
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Fig.1B Wound closure in MEF RKIP
+/+
, MEF RKIP
-/- 
and MEF RKIP
-/-
 GFP RKIP cells 
in the presence of mitomycin C. MEF RKIP
-/-
 GFP RKIP migrates dramatically faster  
than MEF RKIP
-/-
. There is no obviously difference in the rates of migration between 
MEF RKIP
+/+ 
and MEF RKIP
-/-
, but we can still find that MEF RKIP
+/+ 
migrates very 
slightly faster than MEF RKIP
-/-
. 
NLS of RKIP has a regulatory effect on cell migration 
We have demonstrated that RKIP is able to promote cell migration in MEF cell line. To 
determine whether or not NLS of RKIP expression has a regulatory effect on cell 
migration, we reintroduced NLS deficient point mutants of RKIP, which are described in 
construction of stably transfected cell lines of materials and methods part, into MEF 
RKIP
+/+
 and MEF RKIP
-/-
 cells.  Although we have not collected the data for MEF RKIP
-
/-
 cells yet, we can still find an interesting result from the MEF RKIP
+/+ 
cell migration 
data. MEF RKIP
+/+ 
GFP RKIP K148N has a positive effect on cell migration (Appendix 
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Fig.6). However, MEF RKIP
+/+ 
GFP RKIP R155N, MEF RKIP
+/+ 
GFP RKIP K157N and 
MEF RKIP
+/+ 
GFP GST RKIP (1-134) have a negative effect on cell migration 
(Appendix Fig. 8, 10 and 12). Moreover, we also found that MEF RKIP
+/+ 
GFP RKIP 
R146N, MEF RKIP
+/+ 
GFP RKIP K150N, MEF RKIP
+/+ 
GFP RKIP K156N MEF 
RKIP
+/+ 
GFP RKIP R146N K148N K150N, MEF RKIP
+/+ 
GFP RKIP R155N K156N 
K157N and MEF RKIP
+/+ 
GFP GST RKIP showed no effect on cell migration (Appendix 
Fig.3, 5, 7, 9, 11 and 13). 
RKIP has a regulatory effect on cell proliferation 
To determine whether or not RKIP expression had a regulatory effect on cell proliferation, 
we plated MEF cells of the cells in 96-well tissue culture treated plates and measured 
their proliferation over 24 hours with WST-8.  Wild type MEF cells exhibited a slower 
proliferation rate when compared to RKIP deficient RKIP
-/-
 cells (Fig. 2A).  Similarly, 
RKIP
-/-
 cells exhibited a faster rate of proliferation when compared to RKIP
-/-
 cells re-
expressing RKIP (Fig. 2B).    
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Fig. 2A MEF cell proliferation is regulated by RKIP expression.  Wild type MEF RKIP
+/+
 
cells proliferate at a significantly slower rate when compared to MEF RKIP
-/-
. 
NLS RKIP has a regulatory effect on cell proliferation 
We have demonstrated that RKIP is able to reduce the rate of cell proliferation in MEF 
cell line. To determine whether or not NLS of RKIP expression has a regulatory effect on 
cell migration, we reintroduced NLS deficient point mutants of RKIP, which are 
described in construction of stably transfected cell lines of materials and methods part, 
into MEF RKIP
-/-
 cells. Surprisingly, MEF RKIP
-/- 
cells expressing RKIP missing the 
NLS show the tendency to revert to the RKIP 
-/-
 proliferation rate (Fig. 2B). We can 
clearly see that, except for MEF RKIP
-/- 
GFP RKIP K150N, the rest of the MEF RKIP
-/- 
cells with NLS point mutants of RKIP expressed has the similar or higher rate of 
proliferation than MEF RKIP
-/- 
GFP RKIP cells. Therefore, there seems to be a regulatory 
effect NLS of RKIP would have on the cell proliferation of MEF cell line.  
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Fig. 2B MEF cell proliferation is regulated by RKIP expression. MEF RKIP-/- cells with 
RKIP and various RKIP mutants proliferate at a slower rate much like wild type MEF 
RKIP
+/+
 cells. Mutations located in the NLS or completely removing the NLS in the C-
terminus of RKIP negatively affects the proliferative effect observed in MEF RKIP
+/+
 
cells. Asterisks indicate statistical significance (p<0.05 compared to controls) derived 
from three different experiments. 
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RKIP expression regulates cell cycle distributions 
To prove that RKIP expression alone was enough to regulate the cell cycle cultured cells 
deficient in RKIP along with RKIP
-/-
 with RKIP introduced. Following a 24-hour 
incubation the cells were fixed and the cell cycle distribution was analyzed using flow 
cytometry after staining with propidium iodide. Consistent with previous results, RKIP 
expression coincided with a larger amount of cells in the apoptotic and G2/M phases 
when compared to RKIP
-/-
 cells expressing GFP (Fig. 3) 
 
Fig. 3 Deletion of the C terminus of RKIP eliminates effect RKIP has on cell cycle 
distributions in MEF RKIP
-/-
 cells. Cell cycle analysis of unsynchronized MEF RKIP
-/-
 
cells expressing RKIP showed increased apoptosis and a larger amount of cells in S phase 
with a decrease in the amounts of cells in G2/M. MEF RKIP
-/- 
cells expressing RKIP (1-
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134) reverted to MEF RKIP
-/- 
profile. Asterisks indicate statistical significance (p<0.05 
compared to controls) derived from three different experiments. 
RKIP expression has no effect on Raf-1 activation in cells lacking serum stimulation 
To determine whether a lack on nuclear accumulation resulted in decreased Raf-1 activity 
we serum starved and stimulated our engineered cell lines to observe the effect. No 
observable difference was detected after stimulation in all of engineered cell lines (Fig 
4A).  Interestingly, MEF
-/- 
cells with RKIP NLS deficient mutants bound Raf but failed to 
mitigate its activity in the presence of serum stimulation. 
 
Fig. 4A RKIP expression in MEF cells fails to suppress ERK activity in the presence 
of serum stimulation. Western blotting of p-ERK in MEF whole cell lystates after serum 
starvation and subsequent stimulation with 10% serum. Experiment performed in in 
triplicate.  1) MEF RKIP
+/+
, 2) MEF RKIP
-/-
 3) MEF RKIP
-/-
 GFP, 4) MEF RKIP
-/-
 GFP-
RKIP, 5) MEF RKIP
-/-
 GFP-GST-RKIP, 6) MEF RKIP
-/-
 GFP-GST-RKIP(1-134) and 7) 
MEF RKIP
-/-
 GFP-GST-RKIP(60-187). 
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Fig. 4B RKIP expression in MEF cells fails to suppress ERK activity in the presence 
of serum stimulation. Western blotting of Raf in MEF cells after co-
immunoprecipitation of GFP. 1) MEF RKIP
-/- 
GFP, 2) MEF RKIP
-/-
 GFP-RKIP, 3) MEF 
RKIP
-/-
 GFP-RKIP (146-NGNFNVASFNNN-157), 4) MEF RKIP
-/-
 GFP-GST-RKIP, 
and 5) MEF RKIP
-/-
 GFP-GST-RKIP(1-134).   
2.4 Discussion 
RKIP is a multifaceted protein that has been linked to tumor metastasis, cell migration, 
and cell proliferation. However, a consensus on the role RKIP plays in these processes 
has yet to be reached since different groups have seen different results. To study the 
effect RKIP has we decided to study wild type MEF cells along with MEF cells 
completely devoid of RKIP. We then reintroduced RKIP in to the cells lacking RKIP and 
observed some of the more variable results published in the RKIP field. 
RKIP has been shown to inhibit [128, 139, 143], promote [137, 140, 144, 162], and have 
no effect [162] on cell migration. These seemingly contradictory results could depend on 
the migration analysis method in question. For example, some groups favor a larger 
wound and measure the time needed for the cells to fill in the gap created by the 
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wounding mechanism. Although this method is a valid way to measure migration, a 
larger wound takes longer to close allowing for cell division to take place during the 
healing process.  The cell line used could also explain the seemingly variable results. 
Some cell lines migrate faster, making any role RKIP has in the process harder to 
measure. In addition, knockdowns do not completely eliminate the protein in question 
and some of the error could be due to remaining RKIP activity. To address these issues, 
we used MEF
+/+
, MEF
-/-
, MEF
+/+
 +GFP-RKIP and MEF
-/-
 +GFP-RKIP cells to conduct 
the experiment.  We also made small wounds that would lessen the effect cell division 
would have on the migration process.  Considering there is still a remaining effect cell 
division in the wound healing process, we then treated the cells with MMC to eliminate 
this negative effect. We noticed that MMC did significantly slow the rate of cell 
migration (Appendix Fig.1). The data we have collected reveals that RKIP has no effect 
on the cell migration (Fig. 1). Furthermore, we found that MEF RKIP
+/+
 GFP RKIP with 
NLS deficient point mutants of RKIP expressed have a variety of regulatory effects on 
cell migration. The different results exhibited that they have positive, negative, and 
neutral effects on cell migration (Appendix Fig.5-13). The reason for these conflicting 
results is difficult to explain. But, in my opinion, NLS of RKIP still seems to have a 
regulatory function on cell migration. Perhaps some of the mutants do not affect RKIP 
binding to importin α and its translocation to nucleus in which RKIP plays a role in 
modulating the protein expression involved in cell migration process. The mutants that 
showed the opposite regulatory effect on cell migration can be accounted for the 
substitution of the amino acids on NLS disrupting the binding between RKIP and 
importin α preventing RKIP from being transported into nucleus. Without the regulation 
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of protein expression involved in cell migration process by RKIP, the cells exhibit a 
lower rate of cell migration. 
Another biological process that seems to vary depending on the cell type is cell 
proliferation.  A few groups have not seen any link between RKIP and cell proliferation 
[146, 147, 156], while the remainder of the studies have noticed a negative effect on 
proliferation [130, 143, 144, 163].  When comparing wild type MEF cells with RKIP 
deficient MEF cells we noticed that the cells expressing RKIP were proliferating at a 
higher rate (Fig. 2A).  We then introduced GFP and GFP-RKIP into MEF RKIP
-/-
 cells 
and confirmed the role RKIP plays in reducing cell proliferation (Fig. 2B).  Moreover, we 
transfected cells lacking RKIP with GFP-RKIP NLS point mutants and RKIP deletion 
mutants [121]. Interestingly, we found that RKIP 146-NGNFNVASFNNN-157 failed to 
reduce the cell proliferation as MEF RKIP
-/- 
GFP-RKIP did.  However, MEF RKIP
-/- 
GFP-RKIP with single amino acid substitutions on NLS of RKIP still have the same 
regulatory effect on cell proliferation with MEF RKIP
-/- 
GFP-RKIP. Furthermore, GFP-
GST-RKIP and GFP-GST-RKIP (60-187) exhibited regulation of proliferation while the 
GFP-GST-RKIP (1-134) reverted to the RKIP deficient proliferation profile. These 
results suggest that nuclear localization is necessary for RKIP to reduce cell proliferation. 
Although the mechanism that nuclear localization of RKIP regulates the cell proliferation 
remains ambiguous, in my opinion, it can be explained with the similar reason that I 
described above in the discussion part for cell migration. Cell proliferation of MEF cell 
line may be regulated only when RKIP goes into the nucleus and modulates the gene 
expression involved in cell proliferation process. 
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It has been reported that phosphorylation of RKIP causes dissociation of Raf [123] and 
association with centrosomes and kinetochores [130]. The authors found that RKIP 
delepleted cells had lower Aurora B kinase activity [130], and they reasoned that RKIP 
depleted cells could override spindle checkpoints ultimately accelerating the cell cycle 
progression. To determine whether the effect on proliferation could be linked to cell cycle 
progression, we used the mutants that seemed to have the most detrimental effect and 
study the cell distribution by flow cytometry. Consistent with previous results [128, 133, 
135, 164], RKIP seems to increase apoptosis and promote a shift of cell distribution in 
the S phase (Fig. 3).  The authors reasoned that RKIP regulates a checkpoint in G2 that 
cells are required to go through in order to enter M phase.  Absence of RKIP allows the 
cells to skip this checkpoint and proliferate at a higher rate.  
RKIP was first initially found to disrupt the interaction between Raf and MEK 
subsequently preventing the activation of MAPK/ERK pathway [120].  The MAPK/ERK 
pathway has been previously implicated in cell cycle progression [165-170].  To 
determine whether the regulatory effect RKIP seems to have in MEF cells was directly 
related to Raf activation, we serum starved confluent cells for 48 hours and then 
stimulated the cells with the addition of 10% FBS.  Both wild type and RKIP depleted 
MEF cells responded to the stimulus. The GFP-RKIP and GFP-RKIP 
NGNFNVASFNNN expressing cells also exhibited normal Raf activation (Fig. 4A).  
Interestingly, and the GFP-GST-RKIP (1-134) mutant lacking the serine 153 
phosphorylation site still exhibited Raf activation in the presence of serum.  This result 
could imply that a different method of regulation is available or that the protein is 
inactive (Fig. 4B).  To determine whether the C terminus deletion mutant was active we 
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performed pull down experiments for RKIP full length and C terminus deletion mutants.  
We found that RKIP and the RKIP deletion mutant associated with Raf, consistent with 
previous results [121]. Taken together, these results indicate that nuclear localization is 
required for the role regulatory role RKIP plays in both cell migration and cell 
proliferation. In addition, these regulatory activities are independent of Raf-1/MEK/ERK 
signaling pathway. Furthermore, these results also reveal that there may be a new 
signaling pathway in which RKIP has the regulatory function on cell migration and 
proliferation of MEF cell line. To discover what pathway it is, more work needs to be 
done in the future. However, what we know is that RKIP modulates a variety of 
processes in a large number of cell lines.  Conflicting results can be attributed to both 
different cell lines and different methods used to manipulate RKIP expression.  
In summary, we discovered that RKIP has no effect on the rate of migration of MEF cell 
line. RKIP also inhibited proliferation in MEF cell line.  The effects that RKIP has on cell 
migration and proliferation could be linked to its nuclear localization.  We did notice an 
increase in the amount of cells in apoptosis and S phase by flow cytometry in cells 
expressing RKIP, but not cells expressing RKIP without a NLS. We also confirmed that 
Raf activity was not the reason that RKIP reduced cell proliferation.  
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APPENDIX 
 
Fig.1 Mitomycin C can eliminate effect cell division and proliferation have on the rate of 
cell migration. We can obviously see MEF RKIP
+/+
 with mitomycin C treated 
migrates significantly slower than MEF RKIP
+/+
 without mitomycin C treated. 
 
 
Fig.2 GFP introduced into MEF RKIP
+/+ 
does not have any effect on cell migration. MEF 
RKIP
+/+ 
GFP has almost the same rate of cell migration with MEF RKIP
+/+
. 
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Fig.3 GFP GST introduced into MEF RKIP
+/+ 
does not have any effect on cell migration. 
MEF RKIP
+/+ 
GFP GST has almost the same rate of cell migration with MEF 
RKIP
+/+
. 
 
 
Fig.4 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP cells in the presence 
of mitomycin C. 
44 
 
 
 
Fig.5 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP R146N cells in the 
presence of mitomycin C. 
 
 
Fig.6 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP K148N cells in the 
presence of mitomycin C. 
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Fig.7 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP K150N cells in the 
presence of mitomycin C. 
 
 
Fig.8 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP R155N cells in the 
presence of mitomycin C. 
46 
 
 
Fig.9 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP K156N cells in the 
presence of mitomycin C. 
 
 
Fig.10 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP K157N cells in the 
presence of mitomycin C. 
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Fig.11 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP (R146N, K148N, 
K150N) cells in the presence of mitomycin C. 
 
 
Fig.12 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP GST RKIP (1-134) cells 
in the presence of mitomycin C. 
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Fig.13 Wound closure in MEF RKIP
+/+ 
and MEF RKIP
+/+
 GFP RKIP (R155N, K156N, 
K157N) cells in the presence of mitomycin C. 
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